RVMD Q4 2020 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-27.6% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$34M-389.4% margin

Net Income

-$34M-390.9% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

-30.9%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$567M

Total Liabilities

$93M

Stockholders' Equity

$475M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$12M	-27.6%
Gross Profit	$9M	$12M	-27.6%
Operating Income	-$34M	-$20M	-74.2%
Net Income	-$34M	-$15M	-134.3%

Revenue Segments

Collaboration Revenue Related Party

$9M100%